Galinpepimut-S + GM-CSF
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Trial Timeline
Jan 14, 2011 → Sep 30, 2016
NCT ID
NCT01266083About Galinpepimut-S + GM-CSF
Galinpepimut-S + GM-CSF is a phase 2 stage product being developed by SELLAS Life Sciences for Acute Myeloid Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01266083. Target conditions include Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia.
What happened to similar drugs?
20 of 20 similar drugs in Acute Myeloid Leukemia were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01266083 | Phase 2 | Completed |
Competing Products
20 competing products in Acute Myeloid Leukemia